DS-1 (drug)

DS-1
Systematic (IUPAC) name
4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide
Identifiers
CAS Number 372497-52-4 YesY
PubChem CID 979735
IUPHAR/BPS 4183
ChemSpider 849261 YesY
Chemical data
Formula C18H10Br2ClN3OS
Molar mass 511.617 g/mol
  (verify)

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]

See also

References

  1. Wafford, KA; Van Niel, MB; Ma, QP; Horridge, E; Herd, MB; Peden, DR; Belelli, D; Lambert, JJ (2009). "Novel compounds selectively enhance delta subunit containing GABA a receptors and increase tonic currents in thalamus". Neuropharmacology 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200.
This article is issued from Wikipedia - version of the Monday, December 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.